230 filings
Page 5 of 12
DEFA14A
6e2r53
23 May 22
Additional proxy soliciting materials
4:30pm
8-K
meeuxvue
12 May 22
Motus GI Reports First Quarter 2022 Financial Results
4:10pm
8-K
vi5lxquz
21 Apr 22
Regulation FD Disclosure
8:05am
8-K
ra6xbl5slhn
11 Apr 22
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:30pm
424B5
xww3sd2s2c
29 Mar 22
Prospectus supplement for primary offering
4:20pm
S-8
aq8pugfiocsn6s7h
29 Mar 22
Registration of securities for employees
4:15pm
8-K
9tenmz0slbk g69cj3
29 Mar 22
Motus GI Reports Fourth Quarter and Full Year 2021 Financial Results
4:05pm
8-K
j4eglsu
24 Feb 22
Motus GI Granted 180-Day Extension to Meet NASDAQ Minimum Bid Price Requirement
8:10am
8-K
r4ove0r
14 Feb 22
Motus GI Receives FDA Clearance to Market the Pure-Vu® EVS System
6:40am
8-K
08p9a0ooq6r0yeqwb6
16 Dec 21
Motus GI Announces U.S. Patent For The Pure-Vu® System's Automatic Self-Purging Features
8:40am
8-K
10lzkul6g00y5rdp42
12 Nov 21
Motus GI Reports Third Quarter 2021 Financial Results and Provides Corporate Update
8:07am
8-K
hwtjf0m 0qiyiqocahnv
26 Oct 21
Motus GI Announces Presentation of Results from Independent Study of Pure-Vu System in IBP Patients at the 2021 ACG Annual Scientific Meeting
8:12am
8-K
qr2hhilj
8 Sep 21
Motus GI Announces Enrollment of Patients at Second Site in the European Union
8:16am
8-K
857caee63fm73cok
27 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am